In 2010, Azadeh Dastmalchi's journey toward transforming healthcare began with a personal challenge. Her father's aversion to ...

Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...

Wearable diagnostics are poised to transform subjective, episodic measures of disease progression to quantified, continuous data streams, according to some industry experts.

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.